Episode highlights
0:11 Intro
0:57 Aspirin: A historic drug
1:49 The ADAPTABLE Study
4:50 Schuyler Jones, MD, and Manesh Patel, MD
27:56 Outro
CONTINUE TO SITE
OR WAIT null SECS
Advertisement
Advertisement
ADAPTABLE, with Schuyler Jones, MD, and Manesh Patel, MD
The first episode of the Heart Trials podcast series focuses on new ACC 2021 research into aspirin dosages for reduced cardiovascular event risk.
About ADAPTABLE
Published: May 15, 2021
Design: Open-label, randomized, pragmatic trial
Population: 15,076 patients with atherosclerotic cardiovascular disease
Assessment: 81 mg versus 325 mg daily aspirin for reduced risk of death, or hospitalization from myocardial infarction or stroke
Safety outcome: Reduced risk of hospitalization for major bleeding
Findings: No significant difference in outcomes between doses over median 26.2 months
Interesting note: Dose-switching to 81 mg was significant among patients assigned to 325 mg aspirin (42%)
The impact: “More than anything, the process of the trial is important: can we do a pragmatic study on a limited budget in the United States in a relatively short period?”
Introducing Heart Trials, the newest specialty podcast series from HCPLive. Heart Trials is a breakdown of the studies that define modern cardiovascular care, from the researchers who led them.
In this first episode, in alignment with new late-breaking research from the American College of Cardiology (ACC) 2021 Virtual Sessions, study author W. Schuyler Jones, MD, and his colleague Manesh Patel, MD, join to discuss the ADAPTABLE study, presented Saturday morning at the meeting and published online at The New England Journal of Medicine.
Jones is an associate professor of Medicine and Population Health Sciences at the Duke University School of Medicine.
Patel is professor of Medicine and chief of the Division of Clinical Pharmacology and Division of Cardiology at the Duke University School of Medicine.
In contributing to the current debate of optimal daily aspirin dosage for the reduced risk of major cardiovascular events in at-risk patients, Jones and colleagues presented pragmatic findings featuring 15,000-plus participants suggesting that there is little difference in outcomes and safety associated with 81 mg and 325 mg aspirin.
What they did find, however, was a significant rate of participants switching from 325 mg doses assigned at baseline, to the standard practice 81 mg dose.
After running through a brief history of aspirin use in the US and highlighting the key outcomes of ADAPTABLE, Jones and Patel join to provide background into the research, share their opinions on the trials’ clinical impact, and gauge how future research may be shaped by these outcomes.
Listen to Heart Trials on your favorite podcast platforms, including Spotify and Apple Podcasts.
Advertisement
Advertisement